Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Planning for an adaptive design: a case study in COPD.

B Jones1, G Atkinson, J Ward

  • 1Pfizer Global Research and Development, Ramsgate Road, Sandwich, Kent CT13 9NJ, UK. Byron.Jones@pfizer.com

Pharmaceutical Statistics
|November 4, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effects of an antiperspirant with emollients on foot-sweat accumulation and blister formation while walking in the heat.

Journal of the American Academy of Dermatology·1995
Same author

The achievement of isoeffective bronchial mucosal dose during endobronchial brachytherapy.

International journal of radiation oncology, biology, physics·1995
Same author

Entry of microbes into the host: using M cells to break the mucosal barrier.

Current opinion in immunology·1995
Same author

Derivation of the optimum dose per fraction from the linear quadratic model.

The British journal of radiology·1995
Same author

On the nature of the mutation in the nude rat.

Trends in genetics : TIG·1995
Same author

Radiotherapy and chemotherapy for inoperable non-small cell lung cancer.

Postgraduate medical journal·1995
Same journal

Impact of Information Leakage in Platform Trials With Survival Endpoints on Type I Error Control.

Pharmaceutical statistics·2026
Same journal

Harmonic Fowlkes-Mallows Index for Medical Diagnostics Tests and Optimal Cut-Off Point Selection of Binary Diseases.

Pharmaceutical statistics·2026
Same journal

Early Phase Dose-Finding Designs for CAR-T Cell Therapies.

Pharmaceutical statistics·2026
Same journal

Optimizing Randomization Ratios in Clinical Trials With Survival Endpoints.

Pharmaceutical statistics·2026
Same journal

CUI-MET: A Clinical Utility Index Based Analysis and Decision Framework for Dose Optimization in Multiple-Dose, Multiple-Outcome Randomized Trials.

Pharmaceutical statistics·2026
Same journal

Will the Pharmaceutical Industry Need Statisticians in an AI World?

Pharmaceutical statistics·2026
See all related articles

Planning a Phase IIa trial for chronic obstructive pulmonary disease (COPD) involves practical and clinical considerations. Adaptive strategies and statistical methods, including interim analyses, can optimize trial design and reduce costs.

Area of Science:

  • Clinical trial design
  • Respiratory medicine
  • Pharmaceutical development

Background:

  • Chronic obstructive pulmonary disease (COPD) presents significant challenges for clinical trial planning.
  • Optimizing trial efficiency and cost-effectiveness is crucial for advancing COPD research.

Purpose of the Study:

  • To outline practical and clinical considerations for Phase IIa COPD trial planning.
  • To explore adaptive strategies for cost reduction and their statistical implications.
  • To describe the use of EAST software for evaluating study designs with interim analyses.

Main Methods:

  • Review of practical and clinical aspects of Phase IIa COPD trial design.
  • Exploration of adaptive trial strategies and their statistical consequences.

Related Experiment Videos

  • Application of EAST software for simulation of study designs with interim analyses (futility, efficacy).

    • Main Results:

    • Identification of key considerations for Phase IIa COPD trial planning.
    • Evaluation of adaptive designs and their impact on trial cost and statistical validity.
    • Demonstration of EAST software's utility in assessing trial properties.

    Conclusions:

    • Strategic planning incorporating adaptive designs and statistical evaluations is essential for efficient COPD trials.
    • The choice between alternative trial designs should balance clinical objectives with statistical rigor.
    • Interim analyses can enhance trial efficiency and decision-making in COPD research.